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Introduction
Lambert-Eaton myasthenic syndrome (LEMS) is well known 
to be a classical paraneoplastic syndrome of small cell lung car-
cinoma (SCLC). Association of myasthenia gravis (MG) and 
SCLC is rarely known. We report a case of acetylcholine recep-
tor antibody (AChR-ab) positive MG and SCLC. 
Case Report
In June 1987, a 65-year-old African-American man noticed 
a weakness in leg muscles a week before admission to a local 
hospital. Weakness got worse and spread to upper arms. Short-
ness of breath developed, requiring endotracheal intubation and 
ventilatory support. Initially, Guillain-Barré syndrome was sus-
pected. However, spinal fluid evaluation was normal with pro-
tein at 30 mg/dL. CK and muscle biopsy were also normal.
The patient was transferred to the University of Alabama Uni-
versity Hospital. Neurologic examination showed bilateral pto-
sis, marked weakness (1-2 Medical Research Council grade) in 
proximal muscles, moderate (3 Medical Research Council grade) 
weakness in distal muscles, normal reflexes except diminished 
ankle reflex and normal sensory function. Edrophonium test was 
equivocal and another spinal fluid evaluation was also normal 
with protein at 21 mg/dL. Because of marked decremental re-
sponse in the repetitive nerve stimulation (RNS) test, the diag-
nosis of MG crisis was made. Plasmaphresis was initiated to-
gether with prednisone (60 mg a day) and pyridostigmine (540 
mg a day). Third spinal fluid evaluation on the third admission 
date was also normal with protein at 36 mg/dL. Another edro-
phonium test on the 12
th admission date showed a definite posi-
tive response. With continued treatment for MG crisis, MG Foun-
dation of America status was improved from V to IIIa in three 
weeks period of time. 
Chest X-ray showed a nodule (2×3.5 cm) in the right upper 
lobe and hilar adenopathy. CT scan showed a lobulated paren-
chymal mass with a soft tissue density in the right hilar area, 
and many scattered small nodules in the right posterior pleural 
space. Thymoma was not found. Transthoracic needle biopsy 
confirmed the diagnosis of SCLC. The patient was treated with 
three days of chemotherapy (CIS-Platinum and VP-16) for 
SCLC. One month after the chemotherapy, the patient developed 
septicemia and respiratory failure leading to adult respiratory 
distress syndrome and died two months after onset of weakness. 
Nerve conduction study (NCS) on the first admission day: 
Motor NCS showed mild prolongation of terminal latency and 
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low compound muscle action potential (CMAP) amplitude in 
the median (4.8 ms/4 mV), ulnar (3.6 ms/3.0 mV), peroneal 
(7.0 ms/1 mV), and posterior tibial (9.1 ms/0.4 mV) nerves and 
mildly slow motor NCV (38.1 and 37.5 m/s) in two posterior 
tibial nerves. F-wave latency was mildly prolonged in all mo-
tor nerve. Sensory NCS showed low CNAP amplitude and 
mildly slow NCV in the median (40 m/s; 8 μV), ulnar (34.3 m/s; 
7 μV), and sural (33.3 m/s; 2 μV) nerves. These findings were 
interpreted as mild axonal motor-sensory neuropathy. NCS was 
not repeated.
The RNS test on the first admission day showed a low CMAP 
amplitude and a marked decrement at low rate stimulation 
(LRS; 2-5 Hz) and high rate stimulation (HRS; 50 Hz) in the 
abductor digiti quinti muscle, and a low CMAP amplitude and 
a marked decrement at LRS in the orbicularis oculi muscle (Ta-
ble 1).
1 There was an improvement in decrement with edropho-
nium though clinical improvement was equivocal. These were 
interpreted to be indicative of severe MG.
1 Further deteriora-
tion was noted in the RNS test on the 11
th day. On the 12
th day, 
there was minimal improvement in the RNS response. There was 
a definite electrophysiological and clinical improvement with 
edrophonium injection. On the 24
rd day, the RNS test showed 
Table 2. Clinical, electrophysiological and immunological features in four cases of MG with SCLC
Case
Age/
Sex
Clinical feature
Repetitive nerve stimulation test‡ Edropho-
nium test
AChR-
antibody
Treatment Outcome
CMAP (mV) PEF (%) LRS (%)  HRS (%)
Hazard 
  1986
55/M Diplopia and 
  weakness in neck 
  flexor and proximal
  muscles
10 -28
(2 Hz)
-22
(20 Hz)
Positive Negative* Chemotherapy
  and radiation 
  for SCLC 
Pyridostigmine 
  for MG
MG 
  remission 
  in 17 months
Fujita 
  1994
49/M Ptosis, dyspnea,
  proximal muscle
  weakness.difficulty
  in walking, chewing,
  and swallowing.
1.5 or 3.0
-25
(3 Hz)
-70?
(20 Hz)
Positive Negative
Miyoshi
  1995
56/M† Ptosis, proximal 
  muscle weakness
-27
(3 Hz)
-39
(15 Hz)
Positive Negative Chemotherapy
  for SCLC 
Pyridostigmine
  for MG
MG remission 
  in 3 years
Our 
  case
55/M Respiratory failure,
  Ptosis, limb weakness 
  proximally worse
2 to 3.2 +6 to 
+50
- 17 to
 -46
(3 Hz)
-36 to 
-56 
(50 Hz)
Equivo-cal
to positive
Positive Chemotherapy for 
SCLC
Pyridostigmine,
  prednisone, &
  plasma exchange 
  for MG
MG 
  improved
  but death
  in 2 months
*Initially not tested but negative at MG remission, †SCLC found 20 months after MG diagnosis, An artifact? ‡RNS test on ADQ muscle 
except APB muscle in Miyoshi’s case.
-: decrement, +: increment, AChR: acetylcholine receptor, ADQ: abductor digiti quinti muscle, CMAP: compound muscle action poten-
tial, HRS: high rate stimulation, LRS: low rate stimulation, MG: myasthenia gravis, PEF: post-exercise facilitation, RNS: repetitive nerve stimu-
lation, SCLC: small cell lung carcinoma.
Table 1. Repetitive nerve stimulation data
Day 1st day 11th day 12th day 24th day‡ Normal
Muscle ADQ Orbicularis oculi ADQ ADQ ADQ FCU ADQ FCU Orbicularis oculi
CMAP (mV) 3.0 0.3 2.0 3.2 3.0† 6.0 4.0 4.8 3.0 1.1
PEF (%) +50 +6 +17 0 +37
LRS (%)   2 Hz -29 -15* -50 -35 -25 -3 0 0 -7 -8 -8
  3 Hz -17 -46 -38 -6 -6 -10 -7 -9 -8
  5 Hz -24 -26 -24 -11 +3 0 -5 -11 -8
HRS (%) 50 Hz -36 -54 -56 -38 -18 -19
PTE (%)   5 Hz -29 -17 +5 -8 -11
MGFA V V V IIIa
*2 minutes after injection, †3 minutes after injection, ‡2 hour after pyridostigmine by mouth.
-: decrement, +: increment, ADQ: abductor digiti quinti muscle, CMAP: compound muscle action potential, FCU: flexor carpi ulnaris 
muscle, HRS: high rate stimulation, LRS: low rate stimulation, MGFA: MG Foundation of America, PEF: post-exercise facilitation.Ohira M et al.
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normal findings except a decrement at the LRS in the flexor 
carpi ulnaris muscle. At that time, the patient was in MG Foun-
dation of America status IIIa. Single-fiber electromyography 
in the extensor digitorum communis muscle on the 24
th day 
showed markedly increased mean value of mean-consecutive-
difference (174 μs) and frequent blocking in 7 SFPPs (Fig. 1). 
AChR-ab tests were positive by two laboratories: 3.4 (nor-
mal<0.7 nmol/L) and 30.55 (normal <0.03 nmol/L). Voltage 
gated calcium channel antibody was not tested in this patient 
because this test was not available in 1987.
Discussion
Our patient had seropositive MG, SCLC and mild axonal 
motor-sensory neuropathy. Guillain-Barré syndrome was initial-
ly suspected but less likely in view of the repeated normal spi-
nal fluid findings and mild axonal neuropathy in the NCS. Ax-
onal neuropathy is most likely a paraneoplastic syndrome of 
SCLC. 
The RNS tests during MG crisis in our case showed a rather 
typical RNS test of myasthenic crisis: low CMAP amplitude 
and decrement at LRS and HRS. In myasthenic crisis, this pat-
tern was observed in 25% of cases.
2 Lower CMAP, though with-
in normal limit, and decrement at LRS and HRS are a rather 
characteristic pattern in severe MG.
1 With clinical improve-
ment, the CMAP amplitude became normal and decrement at 
LRS was the only abnormality in this case. This is the most co-
mmon RNS pattern in MG.
1 Single-fiber electromyography 
showed findings typical of neuromuscular transmission defect. 
LEMS was ruled out by a lack of an incremental response af-
ter brief exercise [post-exercise facilitation (PEF)] or at HRS.
3 
50% increment in PEF in the abductor digiti quinti muscle at 
the 11
th day is slightly higher than normal 37% limit but defi-
nitely lower than 60% increment, the required criteria for the 
diagnosis of LEMS.
3 Transient increment in PEF or HRS was 
previously reported in a few severe MG cases.
3
Fifty percentage of LEMS patients were known to have car-
cinoma, mostly SCLC.
4 Only three cases showing combined 
MG and SCLC features have been reported (Table 2).
5-7 They 
were male and aged 49 to 56. All three cases were seronega-
tive. In two cases, SCLC was found at the time when the diag-
nosis of MG was made. In Myoshi’s case, SCLC was found 18 
months after the diagnosis of MG. All three cases had classical 
oculo-proximal muscle weakness of MG.
7 One case had bul-
bar weakness. Ours is the only one with MG crisis. Diagnosis 
of MG was confirmed by edrophonium test and decrement at 
LRS (25-28%) and HRS (22-70%). The diagnosis of MG in 
Fujita’s case is questionable in view of “decrement” in 20 Hz 
stimulation due to artifacts and discrepancy in the first CMAP 
amplitude at 3 Hz (1.5 mV) and 20 Hz stimulation (3.0 mV).
5 
This may represent an 100% PEF typical of LEMS. With pyr-
idostigmine therapy for MG and chemotherapy for SCLC, 
MG was in remission in two cases in 17-36 months. Our pa-
tient died 2 months after the diagnosis of MG. No follow-up 
information was available in one case. One may argue that our 
case represents a case of LEMS with positive AChR-ab. 
117
48
83
0.5 mV
0.5 ms
Fig. 1. Three single fiber potential pairs showing a marked jitter. 
Number above single fiber potentials represent MCD value in μs.   
Neuromuscular blocking is noted in the second slave potential in the 
bottom single fiber potential pairs. MCD: mean-consecutive-differ-
ence.Seropositive Myasthenia Gravis Associated with Small-Cell Lung Carcinoma
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Lennon
8 found a positive AChR-ab in 13% of LEMS patients. 
However, electrophysiological findings do not support the di-
agnosis of LEMS. Thus, we believe that our patient is the first 
one with seropositive MG and SCLC.
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